$NKTR

Nektar Therapeutics (NKTR) reported Q2 earnings, highlighting a $1.02B cash balance and Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata. The company expects top-line data in mid-2028 and a potential Biologics License Application submission in 2029. NKTR's operating loss widened to $42.3M, with R&D spending expected to increase. The company raised $373.8M in April 2026 to fund operations.

Nektar Therapeutics reported Q2 2026 earnings with noncash royalty revenue of $10.1M, a net loss of $40.6M, and cash/investments of $1.02B. The company initiated Phase 3 trials for rezpegaldesleukin and updated full-year guidance, including revenue of $40M-$45M and end-of-year cash of $815M-$840M. Management expects a cash runway into Q3 2028, supported by a recent public offering.

U.S. retail sales fell 0.6% in July, per the Department of Commerce, versus a Zacks breakeven; June was 0.2%. Ex-auto retail sales declined 0.3%. Earnings: Applied Materials (AMAT) adjusted EPS $3.50 vs $3.38 est, revenue $9.12B vs +1.31% beat; Nektar (NKTR) adjusted loss $1.23 vs -$2.06 est, revenue $10.13M miss; StoneCo (STNE) EPS $0.47 vs $0.46 est, revenue $709.88M miss.

U.S. stock futures were mixed as the S&P 500 headed for a winning week after a new all-time high. Retail sales fell 0.6% in July, though were up 5% year over year, per the Commerce Department. Earnings: AMAT adjusted EPS $3.50 (vs $3.38 est) on $9.12B revenue; NKTR adjusted loss $1.23 (vs $2.06 est) on $10.13M revenue; STNE adjusted EPS $0.47 (vs $0.46 est) on $709.9M revenue.

Nektar Therapeutics (Nasdaq: NKTR) reported Q2 2026 results. Cash and marketable securities were $1,023.4M at June 30, 2026. Revenue was $10.1M vs $11.2M a year earlier. Operating costs were $52.5M and net loss was $40.6M ($1.23/share). Company said Phase 3 ZENITH AD trials began and cash runway extends into Q3 2028.

NEKTAR THERAPEUTICS (NKTR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Nektar Therapeutics Announces Second Quarter 2026 Financial Results SAN FRANCISCO, Aug 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today reported financial r

A roundup of Wall Street analyst actions on Wednesday includes Stifel upgrading DigitalOcean to buy, Truist upgrading CoreWeave to buy, and multiple initiations: Philip Morris at buy, Affirm at outperform, Nebius at outperform ($250 target), Digital Turbine at buy ($15), CoreWeave at outperform ($100), and DigitalOcean at outperform ($165). Wells Fargo raised Sandisk to equal weight with a $1,620 target; JPMorgan reiterated Shopify overweight. Other calls cover Disney, Fluence Energy, Vornado, a

ROBIN HOWARD W (President & CEO) sold 20,000 shares of NEKTAR THERAPEUTICS (NKTR) at an average of $60.75 ($59.97–$61.65, $1.22M total) across 4 trades over 2026-06-16 to 2026-06-17 under a Rule 10b5-1 trading plan.

NEKTAR THERAPEUTICS (NKTR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0000906709 0000906709 2026-06-05 2026-06-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of repor

The law firm Bronstein, Gewirtz & Grossman, LLC said it is investigating Nektar Therapeutics in connection with potential securities-related matters. The notice does not provide specific allegations or financial figures. The firm’s statement directs questions about the release to the company mentioned in the filing.